Frigerio L, Ansaloni L, Poiasina E, Coccolini F, Sugarbaker PH. Comprehensive management of epithelial ovarian cancer with peritoneal metastases. World J Obstet Gynecol 2013; 2(4): 108-115 [DOI: 10.5317/wjog.v2.i4.108]
Corresponding Author of This Article
Dr. Paul H Sugarbaker, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, United States. paul.sugarbaker@medstar.net
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Obstet Gynecol. Nov 10, 2013; 2(4): 108-115 Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.108
Comprehensive management of epithelial ovarian cancer with peritoneal metastases
Luigi Frigerio, Luca Ansaloni, Elia Poiasina, Federico Coccolini, Paul H Sugarbaker
Luigi Frigerio, Obstetrics and Gynecology Department, Ospedali Riuniti, 24128 Bergamo, Italy
Luca Ansaloni, Elia Poiasina, Federico Coccolini, General and Emergency Surgery Department, Ospedali Riuniti, 24128 Bergamo, Italy
Paul H Sugarbaker, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, United States
Author contributions: All authors were responsible for the conception and design, collection and assembly of data, data analysis and interpretation; Frigerio L, Ansaloni L and Sugarbaker PH were responsible for the provision of study materials or patients and manuscript writing.
Correspondence to: Dr. Paul H Sugarbaker, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, United States. paul.sugarbaker@medstar.net
Telephone: +1-202-8773908 Fax: +1-202-8778602
Received: December 15, 2012 Revised: January 5, 2012 Accepted: January 11, 2013 Published online: November 10, 2013
Abstract
Ovarian cancer has as its predominant pattern of dissemination metastases to the peritoneal surfaces and disease spread within the abdomen and pelvis that most commonly causes the patients demise. To combat peritoneal metastases, cytoreductive surgery with peritoneal and visceral resections is combined with intraperitoneal and systemic chemotherapy. Chemotherapy given in the operating room after the complete visible removal of ovarian cancer is hyperthermic intraperitoneal chemotherapy. The results of the combined treatment are determined by the extent of prior surgery, the extent of disease as established by the peritoneal cancer index, and the quality of the cytoreduction as measured by the completeness of cytoreduction score. Recent clinical information on patients with recurrent ovarian cancer suggest a median overall survival of up to 60 mo. These data are greatly improved over the one year survival observed in the past.
